Patent Specification Concerns Make IPRs Tricky For Drug Cos.

By Dani Kass (January 28, 2022, 8:46 PM EST) -- Attorneys on both sides of drug patent challenges at the Patent Trial and Appeal Board have to be extremely cautious to draft an obviousness argument in a way that doesn't undermine one for written description or enablement, according to an IPWatchdog panel....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!